MSD

News

MSD takes on Pfizer's Prevnar with new Capvaxive approval

MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.

News

MSD steps out with Protillion in $510m+ AI shindig

MSD has teamed up with Protillion Bio in a deal worth more than $510m, focusing on using the AI start-up's lab-in-the-loop platform for drug discovery

News

FDA starts kicks off review of Gilead's weekly HIV pill

The FDA is due to deliver a verdict in February on Gilead's once-weekly pill for HIV PrEP, which could expand the options available to patients.

News

MSD's Sac-TMT delivers in first phase 3 readout

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

News

NICE backs stomach cancer, PAH drugs for NHS use

AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.

News

MSD cuts $1bn AI tool deal with Google Cloud

MSD has agreed a deal with Google Cloud that will put the tech giant's AI tools in the hands of its 75,000 employees worldwide.

MSD takes on Pfizer's Prevnar with new Capvaxive approval

MSD steps out with Protillion in $510m+ AI shindig

FDA starts kicks off review of Gilead's weekly HIV pill

MSD's Sac-TMT delivers in first phase 3 readout

NICE backs stomach cancer, PAH drugs for NHS use

MSD cuts $1bn AI tool deal with Google Cloud

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks